MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-09-2023
NeuBase Therapeutics ROCE Ratio 2011-2026 | NBSE
Annual ROCE Ratio NeuBase Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -143.66 | -49.13 | -54.54 | -262.59 | -83.28 | -103.72 | -101.37 | -41.11 | -34.1 | -87.78 | -135.45 | 26.0 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 26.0 | -262.59 | -89.23 |
Quarterly ROCE Ratio NeuBase Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -50.49 | -83.79 | -86.13 | -112.15 | -102.4 | -104.97 | -92.05 | -90.66 | -91.51 | -93.86 | -92.61 | -84.32 | -121.8 | -137.23 | -151.72 | -189.19 | 240.14 | 220.85 | 237.17 | 281.99 | -114.76 | -122.89 | -128.2 | -140.45 | -146.2 | -92.4 | -105.96 | -112.66 | -94.9 | -75.76 | -53.17 | -33.68 | -43.05 | -46.41 | -46.24 | -52.46 | -80.45 | -103.19 | -120.87 | -144.6 | -248.83 | -298.65 | -299.43 | -294.61 | -129.39 | -27.19 | -378.2 | -334.22 | 18.15 | -377.17 | 10.4 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 281.99 | -378.2 | -96.51 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
-16.8 | $ 3.54 | -0.7 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
-27.26 | $ 3.25 | 3.83 % | $ 229 M |  Schweiz |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
-180.78 | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-119.71 | - | 10.36 % | $ 9.8 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-48.11 | $ 4.16 | -1.42 % | $ 105 M | Schweiz |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
argenx SE
ARGX
|
-211.69 | $ 712.23 | 1.27 % | $ 25 B |  Niderland |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-45.89 | $ 228.93 | -0.91 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.39 | -6.09 % | $ 8.16 B |  Australia |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-65.67 | $ 6.15 | 1.57 % | $ 501 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-35.64 | $ 6.62 | -0.15 % | $ 181 M |  Israel |
 |
BioCardia
BCDA
|
726.39 | $ 1.35 | 6.29 % | $ 28.6 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
-531.85 | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-252.54 | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
-57.76 | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-115.03 | $ 3.58 | -0.28 % | $ 7.79 B | Israel |
 |
Catalyst Biosciences
CBIO
|
10.83 | $ 11.29 | -2.51 % | $ 1.01 B | USA |
 |
Anika Therapeutics
ANIK
|
-41.29 | $ 14.58 | 1.53 % | $ 214 M | USA |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
CNS Pharmaceuticals
CNSP
|
-241.26 | $ 2.32 | -5.51 % | $ 887 K | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-108.03 | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-12.81 | $ 2.69 | 1.7 % | $ 16.9 M | USA |
 |
Curis
CRIS
|
742.61 | $ 0.89 | 3.74 % | $ 5.61 M | USA |
 |
Avenue Therapeutics
ATXI
|
-403.4 | - | -52.27 % | $ 4.45 M | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 93.04 | 2.76 % | $ 27.2 B | Germany |
 |
Autolus Therapeutics plc
AUTL
|
-161.2 | $ 1.51 | -0.33 % | $ 385 M | Britain |
 |
Athira Pharma
ATHA
|
-225.02 | - | - | $ 269 M | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |